Abstract
In prescription-event monitoring in Japan (J-PEM), patients are identified by prescriptions in individual pharmacies where drugs are dispensed. The methodology is somewhat different to that used by the Drug Safety Research Unit in the UK, in that two questionnaires, one to the pharmacist and the other to the doctor are sent for each patient and the method of concurrent control is employed in J-PEM. In the data analysis, the list of events reported as a suspected reaction or a reason for stopping the drug is made to generate a signal. In addition, a signal may be generated for some events with the statistically significant difference of crude rates followed by the regression analysis or a follow-up study. In J-PEM, Medical Dictionary for Regulatory Activities (MedDRA) terminology is used for data entry and data analysis. Lowest level terms (LLTs) in MedDRA are used in data entry while a signal is generated using preferred terms (PTs). However, to generate a signal effectively, some PTs may be grouped as one term. In addition, if two terms are so similar, it may be instructed that one of those two terms is normally selected in data entry to avoid confusion. Many more PEM studies could be undertaken to determine if MedDRA can be used for effective signal generation,but the usefulness of MedDRA in J-PEM is still to be determined.
References
Kubota K. A design for prescription-event monitoring in Japan (J-PEM). Pharmacoepidemiol Drug Saf 1999; 8: 447–56
Kuobta K, Kawabe E, Hinotsu S, et al. Pilot study of prescription-event monitoring in Japan (J-PEM) comparing troglitazone with alternative oral hypoglycaemics. Eur J Clin Pharmacol 2001; 56: 831–8
Yokotsuka M, Aoyama M, Kubota K. The use of a medical dictionary for regulatory activities terminology (MedDRA) in prescription-event monitoring in Japan (J-PEM). Int J Med Inf 2000; 57: 139–53
Brown E, Douglas S. Tabulation and analysis of pharmacovigilance data using the medical dictionary for regulatory activities. Pharmacoepidemiol Drug Saf 2000; 8: 479–89
Acknowledgements
This study was conducted under a grant from the Ministry of Health, Labour and Welfare as a Health Sciences Research Project (‘A pilot study of the Japanese version of Prescription-Event Monitoring’ 1998.4-2001.3). The Japan Pharmaceutical Association (JPA), Japanese Society of Hospital Pharmacies (JSHP), and Japan Medical Association Research Institute (JMARI) are participating in this research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kubota, K. Prescription-Event Monitoring in Japan (J-PEM). Drug-Safety 25, 441–444 (2002). https://doi.org/10.2165/00002018-200225060-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200225060-00008